27 years of historical data (1999–2025) · Healthcare · Medical - Devices
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bruker Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 153.7x P/FCF, 87% above the 5-year average of 82.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.7B | $7.2B | $8.8B | $10.8B | $10.2B | $12.8B | $8.4B | $8.0B | $4.7B | $5.5B | $3.4B |
| Enterprise Value | $8.4B | $8.9B | $10.8B | $11.7B | $10.8B | $13.2B | $8.6B | $8.2B | $4.7B | $5.6B | $3.5B |
| P/E Ratio → | -291.53 | — | 77.13 | 25.34 | 34.35 | 46.36 | 53.07 | 40.45 | 26.11 | 70.04 | 22.29 |
| P/S Ratio | 1.94 | 2.08 | 2.60 | 3.65 | 4.04 | 5.31 | 4.21 | 3.85 | 2.47 | 3.09 | 2.13 |
| P/B Ratio | 2.64 | 2.85 | 4.83 | 7.65 | 9.02 | 11.83 | 8.59 | 8.51 | 5.12 | 7.36 | 4.91 |
| P/FCF | 153.73 | 165.16 | 64.44 | 44.47 | 70.33 | 67.38 | 35.61 | 56.85 | 24.57 | 49.33 | 36.66 |
| P/OCF | 49.64 | 53.33 | 34.87 | 30.89 | 37.21 | 45.43 | 25.19 | 37.40 | 19.52 | 35.36 | 26.26 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Bruker Corporation's enterprise value stands at 18.4x EBITDA, 18% below its 5-year average of 22.5x. The Healthcare sector median is 14.4x, placing the stock at a 28% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.59 | 3.22 | 3.95 | 4.28 | 5.44 | 4.33 | 3.95 | 2.48 | 3.14 | 2.18 |
| EV / EBITDA | 18.41 | 19.49 | 24.78 | 21.22 | 20.78 | 26.18 | 26.16 | 21.74 | 14.36 | 19.92 | 15.14 |
| EV / EBIT | 35.60 | 108.09 | 42.49 | 20.88 | 25.20 | 32.25 | 35.80 | 27.61 | 17.07 | 23.56 | 16.87 |
| EV / FCF | — | 205.44 | 79.60 | 48.14 | 74.63 | 69.09 | 36.59 | 58.29 | 24.66 | 50.14 | 37.40 |
Margins and return-on-capital ratios measuring operating efficiency
Bruker Corporation earns an operating margin of 6.9%. Operating margins have compressed from 14.7% to 6.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -0.4% indicates the company is currently destroying shareholder equity. ROIC of 4.4% represents below-average returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.9% | 45.9% | 49.0% | 51.0% | 51.6% | 50.0% | 47.3% | 48.0% | 47.5% | 46.0% | 46.1% |
| Operating Margin | 6.9% | 6.9% | 7.5% | 14.7% | 17.1% | 17.1% | 12.5% | 14.5% | 13.8% | 12.2% | 11.0% |
| Net Profit Margin | -0.3% | -0.3% | 3.4% | 14.4% | 11.7% | 11.5% | 7.9% | 9.5% | 9.5% | 4.5% | 9.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.4% | -0.4% | 7.0% | 33.6% | 26.8% | 26.9% | 16.5% | 21.3% | 21.7% | 10.9% | 21.3% |
| ROA | -0.1% | -0.1% | 2.2% | 10.9% | 8.2% | 8.3% | 5.4% | 8.0% | 8.8% | 4.2% | 8.7% |
| ROIC | 4.4% | 4.4% | 6.1% | 16.1% | 20.5% | 23.7% | 15.9% | 21.8% | 22.3% | 20.1% | 17.6% |
| ROCE | 5.0% | 5.0% | 6.7% | 15.2% | 16.0% | 16.6% | 11.3% | 16.5% | 17.8% | 15.8% | 14.4% |
Solvency and debt-coverage ratios — lower is generally safer
Bruker Corporation carries a Debt/EBITDA ratio of 4.5x, which is highly leveraged (36% above the sector average of 3.3x). Net debt stands at $1.7B ($2.0B total debt minus $299M cash). Interest coverage of just 1.4x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.81 | 0.81 | 1.24 | 0.98 | 1.12 | 1.28 | 0.94 | 0.94 | 0.37 | 0.56 | 0.59 |
| Debt / EBITDA | 4.48 | 4.48 | 5.14 | 2.50 | 2.44 | 2.77 | 2.78 | 2.34 | 1.04 | 1.49 | 1.78 |
| Net Debt / Equity | — | 0.69 | 1.14 | 0.63 | 0.55 | 0.30 | 0.24 | 0.22 | 0.02 | 0.12 | 0.10 |
| Net Debt / EBITDA | 3.82 | 3.82 | 4.72 | 1.62 | 1.20 | 0.65 | 0.70 | 0.54 | 0.06 | 0.33 | 0.30 |
| Debt / FCF | — | 40.28 | 15.16 | 3.66 | 4.30 | 1.71 | 0.98 | 1.44 | 0.10 | 0.82 | 0.74 |
| Interest Coverage | 1.36 | 1.36 | 5.32 | 34.18 | 26.71 | 28.52 | 16.68 | 18.52 | 21.84 | 15.30 | 15.74 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.73x means Bruker Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.87x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 1.80x to 1.73x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.73 | 1.73 | 1.60 | 1.80 | 2.31 | 2.63 | 2.43 | 2.78 | 2.18 | 2.59 | 2.42 |
| Quick Ratio | 0.87 | 0.87 | 0.77 | 0.99 | 1.44 | 1.88 | 1.56 | 1.89 | 1.33 | 1.66 | 1.58 |
| Cash Ratio | 0.23 | 0.23 | 0.14 | 0.41 | 0.71 | 1.24 | 0.92 | 1.06 | 0.54 | 0.84 | 0.95 |
| Asset Turnover | — | 0.55 | 0.58 | 0.70 | 0.70 | 0.66 | 0.65 | 0.75 | 0.89 | 0.91 | 0.89 |
| Inventory Turnover | 1.70 | 1.70 | 1.61 | 1.50 | 1.53 | 1.70 | 1.51 | 1.87 | 1.95 | 1.96 | 1.97 |
| Days Sales Outstanding | — | 78.17 | 76.03 | 76.56 | 85.86 | 62.93 | 61.58 | 63.79 | 68.78 | 66.00 | 55.25 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bruker Corporation returns 0.5% to shareholders annually — split between a 0.3% dividend yield and 0.2% buyback yield.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.3% | 0.3% | 0.5% | 0.5% | 0.8% |
| Payout Ratio | — | — | 26.7% | 6.9% | 10.0% | 8.7% | 15.6% | 12.7% | 14.0% | 32.3% | 16.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 1.3% | 3.9% | 2.9% | 2.2% | 1.9% | 2.5% | 3.8% | 1.4% | 4.5% |
| FCF Yield | 0.7% | 0.6% | 1.6% | 2.2% | 1.4% | 1.5% | 2.8% | 1.8% | 4.1% | 2.0% | 2.7% |
| Buyback Yield | 0.2% | 0.1% | 0.0% | 1.4% | 2.6% | 1.2% | 1.5% | 1.8% | 0.0% | 2.8% | 4.7% |
| Total Shareholder Yield | 0.5% | 0.5% | 0.3% | 1.7% | 2.9% | 1.4% | 1.8% | 2.1% | 0.5% | 3.3% | 5.4% |
| Shares Outstanding | — | $152M | $150M | $147M | $149M | $153M | $155M | $157M | $157M | $159M | $162M |
Compare BRKR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| $7B | -291.5 | 18.4 | 153.7 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 | |
| $23B | 32.6 | 21.5 | 42.3 | 57.8% | 28.2% | 29.3% | 20.3% | 1.3 | |
| $15B | 35.3 | 20.1 | 110.0 | 68.3% | 16.9% | 7.3% | 6.8% | 1.8 | |
| $19B | 35.0 | 17.5 | 19.2 | 61.0% | 17.7% | 7.0% | 6.0% | 2.6 | |
| $34B | 26.0 | 19.9 | 29.2 | 52.4% | 21.3% | 20.6% | 13.5% | 1.9 | |
| $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 | |
| $27B | 31.3 | 23.4 | 31.6 | 57.5% | 27.8% | — | 40.0% | 1.9 | |
| $36B | 24.8 | 14.6 | 14.6 | 69.2% | 28.3% | 7.9% | 6.1% | 3.0 | |
| $124B | 34.9 | 18.2 | 23.6 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 | |
| $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 | |
| $7B | 9.2 | 16.7 | 18.5 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 | |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Includes 30+ ratios · 27 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationSide-by-side business, growth, and profitability comparison vs Waters Corporation.
Start ComparisonQuick answers to the most common questions about buying BRKR stock.
Bruker Corporation's current P/E ratio is -291.5x. The historical average is 38.5x.
Bruker Corporation's current EV/EBITDA is 18.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.0x.
Bruker Corporation's return on equity (ROE) is -0.4%. The historical average is 12.3%.
Based on historical data, Bruker Corporation is trading at a P/E of -291.5x. Compare with industry peers and growth rates for a complete picture.
Bruker Corporation's current dividend yield is 0.34%.
Bruker Corporation has 45.9% gross margin and 6.9% operating margin.
Bruker Corporation's Debt/EBITDA ratio is 4.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.